@what.thewell's Wegovy pen tutorial, fact-checked
Quick answer
Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The autoinjector pen described in this video is the approved delivery device, and the mechanical injection steps demonstrated are consistent with the manufacturer's instructions for use. Proper storage, site rotation, and disposal are all part of complete patient training and were only partially covered in this tutorial.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @what.thewell actually say?
Dr. Ann Defnet, presenting through Northwell Health's TikTok account, walked viewers through the Wegovy autoinjector pen step by step. The core message: remove the cap, press the pen against your skin, wait for the yellow indicator to finish moving, listen for a click, hold five more seconds, and dispose of the used pen in a sharps container. She called it "very user friendly" and emphasized that "the only thing to get this pen ready is taking off the cap."
This is a procedural how-to video, not a medical claims video. There are no promises about weight loss outcomes, no dosing recommendations, and no comparisons to other drugs. The framing is practical and narrow, which is refreshing by TikTok standards. That said, a few gaps are worth examining closely.
Does the science back this up?
Yes, for the most part. The injection technique described here is consistent with Novo Nordisk's own prescribing information and the clinical trial protocols used in the STEP program. The autoinjector mechanism she describes, cap removal only, no priming, yellow window indicator, audible click, is accurate for the current Wegovy pen design.
The five-second post-click hold is real guidance. It allows the full dose to deposit subcutaneously and reduces the risk of leakage at the injection site. Wilding et al. (2021, New England Journal of Medicine), the flagship STEP 1 trial, used once-weekly subcutaneous semaglutide 2.4 mg, administered exactly this way. The trial's injection training protocols reflect the same cap-only preparation step she describes.
One thing the video does not address is injection site selection. Subcutaneous semaglutide can be injected in the abdomen, thigh, or upper arm, and rotating sites matters for reducing local skin reactions. That omission is not a factual error, but it is a gap in a tutorial targeting new users.
What did they get wrong (or right)?
They got the sharps disposal point right, and it is worth giving real credit here. Most TikTok injection tutorials skip this entirely. Telling viewers "you still can't throw the pens in the trash because there is a needle in here" is accurate and responsible. Needle-stick injuries from improperly discarded autoinjectors are a documented public health issue (Phillips et al., 2016, Waste Management).
The claim that "you just use it once and then you're done with it" is accurate. Each Wegovy pen contains one dose and is single-use by design.
What is missing, and this is a genuine gap, is any mention of storage requirements. Wegovy pens should be stored in a refrigerator at 36-46 degrees Fahrenheit before first use. They can be stored at room temperature (up to 77 degrees Fahrenheit) for up to 28 days, but that detail matters. A patient who leaves their pen in a hot car thinking it is "ready to go" after just removing the cap could be injecting degraded medication. That is a real-world failure mode that a 116,000-view tutorial should address.
What should you actually know?
This video is a competent basic tutorial from a credentialed source, a physician through a major hospital system. The injection mechanics are accurate. The disposal advice is correct. But it leaves out two things that new Wegovy users genuinely need to know.
First, storage. Temperature sensitivity is not a footnote. Semaglutide is a peptide hormone, and heat degrades it. If your pen has been improperly stored, you may be injecting a compromised dose without knowing it. Always check that your pen was cold when you received it from the pharmacy.
Second, injection site rotation. Novo Nordisk's prescribing information explicitly recommends rotating among approved sites (abdomen, thigh, upper arm) and not injecting into areas with active skin conditions or recent scarring. Repeated injection into the same spot can cause lipohypertrophy, a lumpy buildup of fat tissue that impairs absorption, a well-documented problem in insulin-dependent patients and relevant for weekly injectors too (Blanco et al., 2013, Diabetes Care).
If you are starting Wegovy, your prescriber or pharmacist should walk you through a full injection training that covers these points. A 60-second TikTok tutorial is a useful supplement, not a substitute for that conversation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @what.thewell's Wegovy pen tutorial, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Wegovy (semaglutide 2.
FormBlends verdict
Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The autoinjector pen described in this video is the approved delivery device, and the mechanical injection steps demonstrated are consistent with the manufacturer's instructions for use. Proper storage, site rotation, and disposal are all part of complete patient training and were only partially covered in this tutorial.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The autoinjector pen described in this video is the approved delivery device, and the mechanical injection steps demonstrated are consistent with the manufacturer's instructions for use. Proper storage, site rotation, and disposal are all part of complete patient training and were only partially covered in this tutorial.
- The Wegovy autoinjector pen is genuinely single-use and once-weekly, with no mixing, priming, or complex preparation required beyond cap removal.
- The five-second post-click hold is not optional: it allows the full semaglutide dose to deliver subcutaneously and reduces the risk of medication leaking back out at the injection site.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The Wegovy autoinjector pen is genuinely single-use and once-weekly, with no mixing, priming, or complex preparation required beyond cap removal.
- The five-second post-click hold is not optional: it allows the full semaglutide dose to deliver subcutaneously and reduces the risk of medication leaking back out at the injection site.
- Storage matters and was not mentioned in this video: Wegovy pens must be refrigerated at 36-46 degrees Fahrenheit before first use and should not exceed 77 degrees Fahrenheit for more than 28 cumulative days.
- Injection site rotation across the abdomen, thigh, and upper arm is recommended by Novo Nordisk's prescribing information and reduces the risk of lipohypertrophy, a fat-tissue buildup that impairs drug absorption (Blanco et al., 2013, Diabetes Care).
- The sharps disposal guidance is correct and worth repeating: the retracted needle is still inside the used pen, making trash disposal a needle-stick risk and a regulatory violation in most jurisdictions.
- This tutorial comes from a physician at a major hospital system, which makes it a more reliable source than typical TikTok injection content, but it still should not replace full injection training from your prescriber or pharmacist.
- The STEP 1 trial showed 14.9 percent mean body weight reduction with once-weekly subcutaneous semaglutide 2.4 mg versus 2.4 percent with placebo over 68 weeks, but those outcomes depend on proper injection technique and dose delivery (Wilding et al., 2021, NEJM).
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
The Well by Northwell · TikTok creator
116.6K views on this video
This is how to use the Wegovy pen. It’s a once-a-week kind of thing. Get the step-by-step tutorial from Dr. Ann Defnet. #wegovyinstructions #weightlossinjection #glp1support #weeklydose #thewellbynort
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by The Well by Northwell, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.